Grifols, S.a. (NASDAQ:GRFS)

Grifols, S.A., a specialty biopharmaceutical company, develops, manufactures, and distributes plasma derivative products in Spain and internationally. The company specializes in providing infusion solutions, nutrition products, medical devices, diagnostic instrumentation, and reagents for use in hospitals and clinics. Its Bioscience division engages in the manufacture of plasma derivatives for therapeutic use, including the reception, analysis, quarantine, classification, fractionation, and purification of plasma; and sale and distribution of end products. This division offers plasma products, such as IVIG, Factor VIII, A1PI, and albumin; and intramuscular immunoglobulins, ATIII, Factor IX, and plasma thromboplastin components. The company’s Hospital division manufactures and installs products that are used by and in hospitals, such as parenteral solutions and enteral and parenteral nutritional fluids. Its Diagnostic division focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products, including analytical instruments and reagents for diagnostics, as well as blood bank products. This division’s customers include blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The company’s Raw Materials and Others division engages in the sale of intermediate pastes and plasma to third parties. Grifols, S.A.’s products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and a range of other medical conditions. Grifols, S.A. was founded in 1940 and is headquartered in Barcelona, Spain.